NCT03420521View on ClinicalTrials.gov

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

PHASE2TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

March 9, 2018

Primary Completion Date

November 24, 2021

Study Completion Date

November 24, 2021

Conditions

Neuroendocrine TumorsCarcinoid Tumor

Interventions

DRUG

Nivolumab

240mg IV over 60 minutes Q2W

DRUG

Ipilimumab

1mg/kg IV over 30 minutes Q6W

Trial Locations (1)

21287

Johns Hopkins Medical Institution, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03420521 - Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter